EMA Authorised: Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) (split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14)) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

EMA authorised Adjupanrix, a split-virion inactivated adjuvanted influenza vaccine for pandemic influenza (H5N1) using the A/VietNam/1194/2004-like strain; Glax…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• Adjupanrix

Snippet

Status: Authorised. Therapeutic area: Influenza, Human;Immunization;Disease Outbreaks. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 12/02/2025